Breaking News
October 18, 2018 - FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer
October 18, 2018 - Many U.S. adults confused about primary care, study shows
October 18, 2018 - With philanthropic gifts, Stanford poised to make major advances in neurosciences | News Center
October 18, 2018 - Researchers discover why heart contractions are weaker in individuals with HCM
October 18, 2018 - Participation in organized sport during childhood may have long-term skeletal benefits
October 18, 2018 - Probiotic/antibiotic combination could eradicate drug-resistant bacteria
October 17, 2018 - More Socioeconomic Challenges for Hispanic Women With HIV
October 17, 2018 - 49,XXXXY syndrome – Genetics Home Reference
October 17, 2018 - Scientists uncover possible new causes of Tourette syndrome
October 17, 2018 - Girl undergoes unusual heart surgery after compassionate-use exemption | News Center
October 17, 2018 - Health Issues That Are Sometimes Mistaken for Gluten Sensitivity
October 17, 2018 - Elective induction of labor at 39 weeks may be beneficial option for women and their babies
October 17, 2018 - New smart watch algorithms can accurately monitor wearers’ sleep patterns
October 17, 2018 - Researchers demonstrate epigenetic memory transmission via sperm
October 17, 2018 - FDA, DHS announce memorandum of agreement to address cybersecurity in medical devices
October 17, 2018 - Health Tip: Know the Risks of Chicken Pox
October 17, 2018 - Immunotherapy effective against hereditary melanoma
October 17, 2018 - Researchers reveal new mechanism for how animal cells stay intact | News Center
October 17, 2018 - Alzheimer's Goes Under the Cryo-Electron Microscope
October 17, 2018 - Medicare for all? CMS chief warns program has enough problems already
October 17, 2018 - Metrohm Raman introduces Mira P handheld Raman system
October 17, 2018 - Expanding the knowledge about hippocampus to better understand cognitive deficits in MS
October 17, 2018 - Study of Nigerian breast cancer patients reveals prevalence of aggressive molecular features
October 17, 2018 - Many healthy children may have metabolic risk factors, finds study
October 17, 2018 - A new antibiotic could be a better, faster treatment for tuberculosis
October 17, 2018 - “I will not become a Robot Doctor”: A medical student vows to practice compassion
October 17, 2018 - Study findings may explain sporadic outbreaks of C. difficile infections in hospitals
October 17, 2018 - Purdue researchers develop new chemical process to find better drug ‘fits’ for patients
October 17, 2018 - Yale researchers develop way to attack RNA with small-molecule drugs
October 17, 2018 - New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug
October 17, 2018 - Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
October 17, 2018 - Nine cases of polio-like illness suspected in children in illinois
October 17, 2018 - Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries
October 17, 2018 - Patients once thought incurable can benefit from high-dose radiation therapy
October 17, 2018 - Researchers awarded grant to advance testing of experimental heroin vaccine
October 17, 2018 - Researchers examine SSRI use during pregnancy and major gestational malformations
October 17, 2018 - FDA grants Rare Pediatric Disease Designation for Immusoft’s Iduronicrin genleukocel-T
October 17, 2018 - Reliable Respiratory announces acquisition of Attleboro Area Medical Equipment
October 17, 2018 - Study reveals link between childhood abuse and higher arthritis risk in adulthood
October 17, 2018 - Research shows people over 65 are not performing enough physical activity
October 17, 2018 - FDA Approves Liletta (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
October 17, 2018 - Weight gain after smoking cessation linked to increased short-term diabetes risk
October 17, 2018 - Researchers find opportunity to control salt-sensitive hypertension without exercising
October 17, 2018 - Women not warned about cancer associated with breast implants
October 17, 2018 - Metrohm offers robust handheld Raman analyzer for Defense and Security
October 17, 2018 - Modeling Non-Numerical Data in Systems Biology
October 17, 2018 - Research aims to address health disparities in African-American men
October 17, 2018 - Human and cattle decoys trap outdoor-biting mosquitoes in malaria endemic regions
October 17, 2018 - High Circulating Prolactin Level Inversely Linked to T2DM Risk
October 17, 2018 - Study finds gene variant predisposes people to both Type 2 diabetes and low body weight
October 17, 2018 - Metrohm software products make it easy to comply with ALOCA and ALCOA+ guidelines
October 17, 2018 - Network of doctors identify the cause of 31 new conditions
October 17, 2018 - Notable improvement in brain cancer survival among younger patients but not much for elderly
October 17, 2018 - Scientists shed light on roles of transcription factors, TP63 and SOX2, in squamous cell carcinoma
October 17, 2018 - Costs of Medicare Diabetes Prevention Program may be higher than expected reimbursement
October 17, 2018 - Misuse of prescription opioids or benzodiazepines associated with suicidal thoughts
October 17, 2018 - New research seeks to address sex disparities in women’s health
October 17, 2018 - C-Section Rates Have Nearly Doubled Since 2000: Study
October 17, 2018 - Talking to Your Kids About STDs
October 17, 2018 - New classification of periodontal and peri-implant diseases and conditions
October 17, 2018 - Herbert D. Kleber, Pioneer in Addiction Treatment, Dies at 84
October 17, 2018 - Health effects of smoke-filled atmosphere
October 17, 2018 - Down syndrome may hold important clues to onset of Alzheimer’s disease
October 17, 2018 - A special report on US’ aging societies
October 17, 2018 - Birth mode may have acute effects on neurodevelopment, study suggests
October 17, 2018 - Global health innovation system fails to deliver affordable treatments to patients, says report
October 17, 2018 - Simple, inexpensive test quickly detects antibiotic-resistant ‘superbugs’
October 17, 2018 - New drugs could reduce risk of heart disease when added to statins
October 17, 2018 - Visible and valued: Stanford Medicine’s first-ever LGBTQ+ Forum
October 17, 2018 - HVP vaccination not linked with rise in teen risky sex
October 17, 2018 - Potential ‘early warning markers’ for sepsis discovered
October 17, 2018 - Who knew? Life begins (again) at 65
October 17, 2018 - Application of blood pressure guidelines ups treatment
October 17, 2018 - Stanford researchers find that small molecule may help treat enzyme deficiency
October 17, 2018 - Speed Cameras Save Money and Lives in New York City
October 17, 2018 - Men who conform to ‘the man box’ more likely to consider suicide and violence
October 17, 2018 - Researchers aim to create more authentic organoids for drug testing, transplantation
October 16, 2018 - New blood test for pediatric brain tumor patients offers safer approach than surgical biopsies
October 16, 2018 - Age-related estrogen increase may be the culprit behind inguinal hernias in men
October 16, 2018 - Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
FDA Alert: Injectable Silicone for Body Contouring and Enhancement: FDA Safety Communication

FDA Alert: Injectable Silicone for Body Contouring and Enhancement: FDA Safety Communication

image_pdfDownload PDFimage_print

November 14, 2017

Audience: Patient, Plastic Surgery, Dermatology, Surgery

[Posted 11/14/2017]

ISSUE: The FDA is alerting the public and health care providers that injectable silicone is not approved to enhance or augment the body. Such use can lead to ongoing pain, infections, and serious injuries, such as scarring and permanent disfigurement, embolism (blockage of a blood vessel), stroke, and death.

The FDA is aware of cases where patients have received injectable silicone for body contouring purposes, such as gluteal or breast enhancement (“butt fillers” or “breast fillers”), by unqualified providers posing as doctors or licensed healthcare practitioners in non-clinical settings such as residential homes or hotels. The FDA is aware that some injectors have falsely told consumers they were receiving an FDA-approved dermal filler, but consumers were instead injected with silicone.

Injectable silicone is permanent, with side effects that can occur right after the injection and up to years after treatment. Silicone spreads and migrates easily inside the body, which may worsen adverse events and make surgical attempts to remove the silicone oil more difficult or impossible. Silicone, when injected into areas with many blood vessels such as the buttocks, can travel to other parts of the body and block blood vessels in the lungs, heart, or brain. This can result in permanent damage to those tissues and lead to stroke or death.

Surgery to remove large-scale injectable silicone may present additional risks and serious complications, and may not entirely rid the body of the silicone. Multiple medical and surgical interventions are sometimes needed to treat symptoms years after initial injection; even then, patients may continue to experience ongoing pain, infection, and scarring and permanent disfigurement requiring ongoing treatment.

The FDA is monitoring reports of adverse events associated with the use of injectable silicone and other unapproved materials and will update the public if significant new information becomes available.

BACKGROUND: Silicone oil is a liquid polymer of siloxane that can be used in products such as lubricants and caulking materials. FDA has not approved injectable silicone (silicone oil) for large-scale body contouring or enhancement. Injectable silicone is different from silicone oil used in small amounts in the eyes and from the silicone used to fill FDA-approved breast implants. The only FDA-approved injectable silicone is silicone oil used for specific intraocular ophthalmic (inside the eye) use.

RECOMMENDATION: The FDA recommends that you do not inject silicone to achieve breast, muscle, or buttocks enhancement.

Healthcare Providers:

  • Be aware that:
    • The use of silicone oil outside intraocular ophthalmic use is not approved by the FDA.
    • Silicone injections used for body enhancement have resulted in serious injuries or death.
    • When treating patients after injections for body contouring, the type of material used may be unknown.
    • When treating patients who have received silicone injections, the material injected may migrate during revision surgery, which may worsen adverse events and make attempts to remove the injectable silicone oil difficult, incomplete, or impossible.
  • Educate health care facility staff on how to quickly identify and assist patients who report signs and symptoms of complications from injectable silicone. Staff must understand how to instruct patients to receive appropriate medical care if a serious adverse reaction occurs such as difficulty breathing or signs of a stroke (including sudden difficulty speaking, numbness or weakness in the face, arms, or legs, difficulty walking, face drooping, severe headache, dizziness, or confusion) during or shortly after a procedure.
  • Discuss the benefits and risks of FDA-approved options for body contouring with patients.

Recommendations for Consumers: Injectable Silicone

  • Do not get injectable silicone or any type of filler material for large-scale body contouring or enhancement. This means you should never get an injectable filler as a breast filler, “butt filler,” or filler for spaces between your muscles. The FDA is aware of serious medical problems and multiple deaths associated with such use. (See the Summary of Problem and Scope section above for more information.)
  • Know that there are no FDA-approved injectable silicone products for body contouring, or to increase the size of areas such as the breasts or buttocks. The only approved uses for dermal fillers are available on the FDA Dermal Fillers website.
  • Seek medical attention immediately if you experience problems such as difficulty breathing, chest pain, signs of a stroke (including sudden difficulty speaking, numbness or weakness in your face, arms, or legs, difficulty walking, face drooping, severe headache, dizziness, or confusion) after receiving injectable silicone, as it may be a life-threatening situation. Be sure to let your health care provider know you have had silicone injections.
  • Seek appropriate medical care, such as from a licensed board-certified plastic surgeon, if you have had silicone oil injections and are experiencing side effects such as pain, hardening of the skin, lumps, or infections.
  • If you believe you have been offered or have received injectable silicone for body contouring from an unlicensed provider, you are encouraged to use the FDA website to report suspected criminal activity.
  • If you are considering a body enhancement or body contouring procedure, only see a licensed health care provider who has appropriate training and experience (e.g., plastic surgeon).

Recommendations for Consumers: FDA-Approved Dermal Fillers

  • Before deciding to have any sort of filler injections, talk with your licensed health care provider about appropriate treatment injection sites and the risks associated with the procedure as well as the product being injected. Know that FDA-approved dermal fillers are not indicated for everyone.
  • Only get FDA-approved dermal fillers injected by licensed health care providers. These health care providers should have appropriate training and experience and should be knowledgeable about the anatomy at and around the injection site.
  • When getting any sort of injectable filler, ask your health care provider for the FDA-approved product brochure and patient labeling. ◦Ask questions and read and discuss the patient labeling for the specific filler you are receiving.
    • Check the FDA website on approved dermal fillers prior to receiving treatment to confirm that the product has been approved by the FDA.
    • Confirm the credentials of your health care provider and the material being injected, and avoid receiving treatment outside of a medical clinic.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report Online: www.fda.gov/MedWatch/report
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

[11/14/2017 – Safety Communication – FDA] en Español
[11/14/2017 – Consumer Update – FDA]

Tagged with:

About author

Related Articles